The Japanese manufacturer of Opto-digital products, Olympus Corporation, is acquiring Quest Photonic Devices B.V. for approximately 50 million euros, the company has just announced. As a manufacturer of optical and digital precision technology, Olympus is thus further expanding its portfolio in the field of precision surgery.
Quest delivers innovative multispectral imaging technologies and state-of-the-art imaging systems in medical applications. The Netherlands-based company has developed innovative fluorescence imaging systems (FIS) to support surgeons in the endoscopic sector. The technology is also used in cancer treatment, as the multispectral imaging system contains a multispectral camera that can visualize the differences between cancer cells and normal healthy tissue. The naked eye cannot do this. Fluorescent imaging, or imaging products, can bring out specific anatomical structures that would not be visible without this technology. Certain dyes combined with special light waves can thus reveal tissues and lesions during surgical endoscopy operations that are not noticeable with normal white light.
Quest’s flagship product is Quest Spectrum, which can be used in fluorescence image-guided surgery related to open and minimally invasive procedures.
FIS imaging technologies will grow rapidly, as evidenced by a 12 percent compound annual growth rate, industry experts say. From about $310 million in 2018, it is expected to reach $827 million in 2027.
More and more new fluorescent dyes are being developed that could be used in various cancer operations, for example. These could then be used in combination with targeted antibodies to support therapy. To make progress in the field of molecular imaging with novel dyes, Quest has joined forces with other biotechnology companies.